Skip to content

ACADIA Pharmaceuticals

US · ACAD #2404 by market cap Listed 1970
17.11 -0.48 -2.73%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 17.45 -0.80%
After-hours 17.12 +0.06%
30.5716.5017.112026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ACAD?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -33.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 4.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation B

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 8.1x Better than 88%
Forward P/E 19.0x Better than 40%
Price / Sales 2.7x Better than 47%
P/E vs own 5-yr range 55th pctl Better than 54%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 91.7% Better than 97%
Operating margin 9.8% Better than 51%
Net margin 36.5% Better than 94%
Return on equity 39.9% Better than 92%
Return on invested capital 35.6% Better than 97%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -42.0% Better than 9%
6-month return -18.9% Better than 28%
12-month return (ex latest month) -16.3% Better than 18%
Distance below 52-week high 44.7% Better than 24%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.8x Better than 80%
Debt to assets 3.3% Better than 83%
Interest coverage -528.7x Better than 2%
Free cash flow / net income 26.9% Better than 7%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 76.9% Better than 57%
Upside to average target 85.7% Better than 80%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.75%
1M -16.29%
3M -41.08%
6M -18.33%
YTD -35.94%
1Y -25.28%
3Y -25.35%
5Y -10.65%

Key statistics

Price & volume

Prev close
17.59
Open
17.47
Day range
17.05 - 17.79
Avg price
17.32
Volume
1.90M
Turnover
32.96M
Amplitude
4.21%
52-week range
15.86 - 30.96

Valuation

P/E
7.44
P/E (TTM)
8.07
P/B
2.13
EPS
2.30
Net profit
397.51M
Net assets
1.39B

Share structure

Market cap
2.96B
Float cap
2.21B
Shares out
172.83M
Float shares
129.32M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 8% of range
15.86 30.96

44.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-48.72M net over the window

Short interest

Shares short
8.32M
As of
2026-10-30

Frequently asked questions

What is the current stock price of ACADIA Pharmaceuticals (ACAD)?

ACADIA Pharmaceuticals last traded at 17.11. This page shows a periodic quote snapshot. Check the displayed quote time.

What is ACADIA Pharmaceuticals's market cap?

About 2.96B.

What is the P/E ratio of ACADIA Pharmaceuticals?

The trailing twelve-month P/E is 8.07. The Valuation tab shows it against the stock's own five-year range.

Does ACADIA Pharmaceuticals pay a dividend?

ACADIA Pharmaceuticals does not currently pay a regular dividend.

Is ACADIA Pharmaceuticals a buy according to analysts?

The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 31.77, which implies 85.7% upside from the current price. This is not investment advice.

What is ACADIA Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates ACADIA Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ACADIA Pharmaceuticals discussion 0 comments

Add a comment